Q-omics provides the consensus-scored DIRAS2 profile across patient tissues and cancer cell-line models. DIRAS2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, DIRAS2 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, DIRAS2 RNA expression shows 17,540 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, and GBM as cancer lineages where DIRAS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DIRAS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DIRAS2 survival associations across molecular data types. DIRAS2 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DIRAS2 RNA expression–survival associations across cancer types. High DIRAS2 expression shows unfavorable associations in COAD, UVM, UCEC and MESO, but favorable associations in KIRC and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for DIRAS2 RNA expression.
This table summarizes DIRAS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for DIRAS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DIRAS2 shows lower tumor expression in THCA, COAD and KICH and higher tumor expression in KIRC, KIRP and LIHC. The KIRC box plot shows higher DIRAS2 RNA expression in tumor versus normal tissue (log2 FC = +2.851, t-test p < 0.001).
This table shows molecular features associated with DIRAS2 in patient tissues and cancer cell lines. In patient samples, DIRAS2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, DIRAS2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and LUNG_SCLC.
